AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

September 9, 2020

Study Completion Date

September 9, 2020

Conditions
Glabellar Lines
Interventions
DRUG

AGN-151586

AGN-151586 solution for injection.

DRUG

Placebo

Placebo solution for injection.

Trial Locations (9)

28403

Wilmington Dermatology Center /ID# 237055, Wilmington

78660

Austin Institute for Clinical Research /ID# 237135, Pflugerville

78759

DermResearch Inc. /ID# 234483, Austin

94538

Center for Dermatology Clinical Research /ID# 237798, Fremont

90404-2208

Ava T. Shamban MD - Santa Monica. /ID# 235353, Santa Monica

33137-3254

Skin and Cancer Associates, LLP /ID# 236231, Miami

46260-2386

Laser and Skin Surgery Center of Indiana /ID# 236588, Indianapolis

19073-2228

Kgl, Llc /Id# 234798, Newtown Square

77056-4129

Austin Institute for Clinical Research at SBA Dermatology /ID# 236646, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY

NCT04096326 - AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines | Biotech Hunter | Biotech Hunter